Organon's fourth quarter of 2025 saw total revenue decline by 5% to $1.507 billion, with a reported net loss of $205 million, or $0.79 per diluted share, primarily due to a $301 million goodwill impairment. Adjusted EBITDA decreased by 15% to $383 million.
Total revenue for Q4 2025 was $1.507 billion, a 5% decrease from Q4 2024.
The company reported a net loss of $205 million in Q4 2025, compared to a net income of $109 million in Q4 2024.
Diluted earnings per share (EPS) was -$0.79, a significant decline from $0.42 in Q4 2024.
Adjusted EBITDA for Q4 2025 was $383 million, down 15% from $448 million in Q4 2024.
Organon expects to achieve approximately $6.2 billion in revenue and $1.9 billion in Adjusted EBITDA for the full year 2026, maintaining performance in-line with 2025, with favorable currency translation offsetting revenue foregone from the JADA® system divestiture.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance